vs
Side-by-side financial comparison of ACNB CORP (ACNB) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ACNB CORP is the larger business by last-quarter revenue ($47.2M vs $28.1M, roughly 1.7× ARS Pharmaceuticals, Inc.). ACNB CORP runs the higher net margin — 22.9% vs -147.1%, a 170.0% gap on every dollar of revenue. On growth, ACNB CORP posted the faster year-over-year revenue change (42.2% vs -67.6%).
ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
ACNB vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $28.1M |
| Net Profit | $10.8M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 27.9% | -147.6% |
| Net Margin | 22.9% | -147.1% |
| Revenue YoY | 42.2% | -67.6% |
| Net Profit YoY | 63.8% | -182.8% |
| EPS (diluted) | $1.10 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.2M | $28.1M | ||
| Q3 25 | $50.9M | $32.5M | ||
| Q2 25 | $50.3M | $15.7M | ||
| Q1 25 | $43.5M | $8.0M | ||
| Q4 24 | $33.2M | $86.6M | ||
| Q3 24 | $34.1M | $2.1M | ||
| Q2 24 | $33.3M | $500.0K | ||
| Q1 24 | $31.6M | $0 |
| Q4 25 | $10.8M | $-41.3M | ||
| Q3 25 | $14.9M | $-51.2M | ||
| Q2 25 | $11.6M | $-44.9M | ||
| Q1 25 | $-272.0K | $-33.9M | ||
| Q4 24 | $6.6M | $49.9M | ||
| Q3 24 | $7.2M | $-19.1M | ||
| Q2 24 | $11.3M | $-12.5M | ||
| Q1 24 | $6.8M | $-10.3M |
| Q4 25 | 27.9% | -147.6% | ||
| Q3 25 | 37.2% | -163.7% | ||
| Q2 25 | 29.7% | -302.9% | ||
| Q1 25 | -1.3% | -466.3% | ||
| Q4 24 | 24.8% | 54.5% | ||
| Q3 24 | 27.6% | -1051.6% | ||
| Q2 24 | 42.8% | -3068.0% | ||
| Q1 24 | 26.9% | — |
| Q4 25 | 22.9% | -147.1% | ||
| Q3 25 | 29.2% | -157.4% | ||
| Q2 25 | 23.2% | -285.6% | ||
| Q1 25 | -0.6% | -425.7% | ||
| Q4 24 | 19.9% | 57.7% | ||
| Q3 24 | 21.1% | -925.0% | ||
| Q2 24 | 33.9% | -2503.2% | ||
| Q1 24 | 21.4% | — |
| Q4 25 | $1.10 | $-0.41 | ||
| Q3 25 | $1.42 | $-0.52 | ||
| Q2 25 | $1.11 | $-0.46 | ||
| Q1 25 | $-0.03 | $-0.35 | ||
| Q4 24 | $0.77 | $0.52 | ||
| Q3 24 | $0.84 | $-0.20 | ||
| Q2 24 | $1.32 | $-0.13 | ||
| Q1 24 | $0.80 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $65.6M | $245.0M |
| Total DebtLower is stronger | $255.4M | $96.4M |
| Stockholders' EquityBook value | $420.0M | $114.3M |
| Total Assets | $3.2B | $327.7M |
| Debt / EquityLower = less leverage | 0.61× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.6M | $245.0M | ||
| Q3 25 | $102.1M | $288.2M | ||
| Q2 25 | $103.1M | $240.1M | ||
| Q1 25 | $123.6M | $275.7M | ||
| Q4 24 | $47.3M | $314.0M | ||
| Q3 24 | $58.1M | $204.6M | ||
| Q2 24 | $86.3M | $218.7M | ||
| Q1 24 | $53.1M | $223.6M |
| Q4 25 | $255.4M | $96.4M | ||
| Q3 25 | $255.4M | $96.2M | ||
| Q2 25 | $255.4M | — | ||
| Q1 25 | $255.3M | — | ||
| Q4 24 | $255.3M | $0 | ||
| Q3 24 | $255.3M | — | ||
| Q2 24 | $255.3M | — | ||
| Q1 24 | $255.3M | — |
| Q4 25 | $420.0M | $114.3M | ||
| Q3 25 | $408.6M | $147.7M | ||
| Q2 25 | $395.2M | $192.3M | ||
| Q1 25 | $386.9M | $229.0M | ||
| Q4 24 | $303.3M | $256.8M | ||
| Q3 24 | $306.8M | $201.0M | ||
| Q2 24 | $289.3M | $215.2M | ||
| Q1 24 | $279.9M | $223.9M |
| Q4 25 | $3.2B | $327.7M | ||
| Q3 25 | $3.3B | $372.8M | ||
| Q2 25 | $3.3B | $313.5M | ||
| Q1 25 | $3.3B | $327.3M | ||
| Q4 24 | $2.4B | $351.2M | ||
| Q3 24 | $2.4B | $217.6M | ||
| Q2 24 | $2.5B | $222.0M | ||
| Q1 24 | $2.4B | $227.6M |
| Q4 25 | 0.61× | 0.84× | ||
| Q3 25 | 0.62× | 0.65× | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.84× | 0.00× | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.6M | $-43.5M |
| Free Cash FlowOCF − Capex | $52.6M | — |
| FCF MarginFCF / Revenue | 111.4% | — |
| Capex IntensityCapex / Revenue | 2.3% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $92.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.6M | $-43.5M | ||
| Q3 25 | $23.2M | $-47.0M | ||
| Q2 25 | $17.8M | $-39.6M | ||
| Q1 25 | $-71.0K | $-40.7M | ||
| Q4 24 | $39.8M | $42.0M | ||
| Q3 24 | $13.6M | $-14.5M | ||
| Q2 24 | $9.7M | $-7.3M | ||
| Q1 24 | $10.8M | $-6.7M |
| Q4 25 | $52.6M | — | ||
| Q3 25 | $22.8M | $-47.2M | ||
| Q2 25 | $17.6M | $-39.6M | ||
| Q1 25 | $-730.0K | $-40.8M | ||
| Q4 24 | $38.8M | $41.7M | ||
| Q3 24 | $13.3M | $-14.6M | ||
| Q2 24 | $9.4M | $-7.3M | ||
| Q1 24 | $10.7M | $-6.8M |
| Q4 25 | 111.4% | — | ||
| Q3 25 | 44.7% | -145.4% | ||
| Q2 25 | 35.0% | -252.2% | ||
| Q1 25 | -1.7% | -512.1% | ||
| Q4 24 | 117.0% | 48.2% | ||
| Q3 24 | 39.1% | -706.3% | ||
| Q2 24 | 28.3% | -1463.4% | ||
| Q1 24 | 33.9% | — |
| Q4 25 | 2.3% | 0.0% | ||
| Q3 25 | 0.8% | 0.6% | ||
| Q2 25 | 0.4% | 0.3% | ||
| Q1 25 | 1.5% | 1.1% | ||
| Q4 24 | 2.9% | 0.3% | ||
| Q3 24 | 0.7% | 6.8% | ||
| Q2 24 | 0.9% | 7.6% | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | 0.84× | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNB
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
